Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · DNA X, Inc. (SONM)

DNA X regains Nasdaq stockholders' equity compliance; faces one-year panel monitor

Mixed Impact 3 of 5 legal/regulatory Written later

DNA X, Inc. received a letter on August 28, 2026, from a Nasdaq Hearings Panel saying the company has regained compliance with the $2.5 million stockholders' equity requirement. The company's securities remain subject to delisting if it fails to maintain compliance with all Nasdaq listing rules through November 18, 2026, and it is under a mandatory panel monitor until August 28, 2027. If the company falls below the equity requirement again during that period, it would get no compliance plan or extra time, and its securities could be delisted.

Key points

  • Panel determined the company regained compliance with the $2.5 million stockholders' equity requirement; letter dated August 28, 2026
  • Securities remain subject to delisting if the company fails to maintain compliance with all Nasdaq rules until November 18, 2026
  • Mandatory panel monitor runs until August 28, 2027; a new equity deficiency would lead to a delisting determination with no cure period

The filing

CompanyDNA X, Inc. (SONM)
Form8-K, current report
Filed with the SECAug 31, 2026, 4:59 PM ET
Accession number0001493152-26-040845

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 31, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.